Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer

Clinical Cancer Research

Volumn 22, Issue 3, 2016, Pages 670-679

  Yun, Eun Jin ^a   Zhou, Jiancheng ^a,b   Lin, Chun Jung ^a,c   Hernandez, Elizabeth ^a   Fazli, Ladan ^d   Gleave, Martin ^d   Hsieh, Jer Tsong ^a,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CD24 ANTIGEN; DOCETAXEL; HERMES ANTIGEN; IWP 2; LKG 974; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN DAB2IP; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DAB2IP PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PROTEIN BINDING; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; ANIMAL; CANCER STEM CELL; CELL TRANSFORMATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TRANSFORMED CELL LINE; TUMOR CELL LINE; TUMOR STEM CELL ASSAY; XENOGRAFT;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MALE; MICE; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN BINDING; RAS GTPASE-ACTIVATING PROTEINS; TAXOIDS; TUMOR STEM CELL ASSAY; WNT SIGNALING PATHWAY;

EID: 84959018543     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0190     Document Type: Article

References (50)

1. Li F, Tiede B,Massague J, Kang Y. Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res 2007;17:3-14.
2. Qin J, Liu X, Laffin B, Chen X, ChoyG, Jeter CR, et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012;10:556-69.
3. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008;68:9703-11.
4. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-65.
5. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260-7.
6. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
7. Mielgo A, Van Driel M, Bloem A, Landmann L, Gunthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 2006;13:465-77.
8. Draffin JE,McFarlane S, Hill A, Johnston PG, Waugh DJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bonemarrow endothelial cells. Cancer Res 2004;64:5702-11.
9. Liu AY, True LD, LaTray L, Ellis WJ, Vessella RL, Lange PH, et al. Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 1999;40: 192-9.
10. Tsai YS, Lai CL, Lai CH, Chang KH, Wu K, Tseng SF, et al. The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget 2014;5:6425-36.
11. Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A 2010;107:2485-90.
12. Yun EJ, Baek ST, Xie D, Tseng SF, Dobin T, Hernandez E, et al. DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1. Oncogene 2015;34:2741-52.
13. Marian CO, Yang L, Zou YS, Gore C, Pong RC, Shay JW, et al. Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line. Prostate 2011;71:626-36.
14. Weijerman PC, Konig JJ, Wong ST, Niesters HG, Peehl DM. Lipofectionmediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 1994;54:5579-83.
15. Xu D, Lin TH, Li S, Da J,Wen XQ, Ding J, et al. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer lett 2012;316:11-22.
16. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A 2007;104:181-6.
17. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002;8:22-8.
18. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004;10:7994-8004.
19. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
20. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, et al. Epithelial to mesenchymal transition ismechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010;5:e12445.
21. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. Prostate 1996; 29:386-94.
22. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-806.
23. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993;19: 351-86.
24. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013;2:3.
25. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, et al. Growthinhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008;134:62-73.
26. Hwang C. Overcoming docetaxel resistance in prostate cancer: A perspective review. Ther Adv Med Oncol 2012;4:329-40.
27. Carson CC, 3rd. Carcinoma of the prostate: Overview of the most common malignancy in men. North Carolina Med J 2006;67:122-7.
28. ClarkeMF, Dick JE,Dirks PB, Eaves CJ, Jamieson CH, JonesDL, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-44.
29. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: A meta-analysis of 1446 patients. BJU Int 2007;99:1056-65.
30. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
31. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16:286-94.
32. Haegel H, Dierich A, Ceredig R. CD44 in differentiated embryonic stem cells: Surface expression and transcripts encoding multiple variants. Dev Immunol 1994;3:239-46.
33. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purifiedCD44+prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-708.
34. Zoller M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;11:254-67.
35. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A 1992;89: 12160-4.
36. Legras S, Gunthert U, Stauder R, Curt F, Oliferenko S, Kluin-Nelemans HC, et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 1998;91:3401-13.
37. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
38. Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate 2014;74:602-17.
39. Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, et al. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer 1996;78:1461-9.
40. NagabhushanM, PretlowTG, Guo YJ, Amini SB, Pretlow TP, SyMS. Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol 1996;106:647-51.
41. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture. Prostate 1998;34:162-8.
42. Maltzman JS, Carman JA, Monroe JG. Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes. Mol Cell Biol 1996;16:2283-94.
43. Foster LC, Wiesel P,Huggins GS, Panares R, Chin MT, Pellacani A, et al. Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1beta in vascular smooth muscle cells. FASEB J 2000;14:368-78.
44. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013;13:11-26.
45. Zeilstra J, Joosten SP, DokterM, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 2008;68:3655-61.
46. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
47. Yardy GW, Brewster SF. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 2005;8:119-26.
48. LeeGT, Kang DI, Ha YS, Jung YS, Chung J, Min K, et al. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Br J Cancer 2014;110:1634-44.
49. Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: Was P-gpnothing but the first head of theHydra? Leukemia 2007;21:1172-6.
50. Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 2013;10:191-210.